On Wednesday, Q32 Bio Inc. QTTB revealed topline results from the SIGNAL-AA Phase 2a signal finding trial evaluating bempikibart (ADX-914) for alopecia areata (AA).The company plans to expand the SIGNAL-AA Phase 2a clinical trial and enroll additional patients evaluating bempikibart in AA.The company said the trial did not meet its primary endpoint in Part B. Q32 Bio plans to review the results.Following database lock, one site was excluded from the efficacy analysis based on marked protocol violations of e ...